Page 2 - Result Poll News Today

Analysts expect a ramp-up in select specialty products to offset some impact of restrictions at Halol and Mohali plants for Sun Pharma.

Based on the mean consensus of four brokerage firms, the company is expected to report a 7.18 percent YoY increase in its revenue at Rs 4,280 crore in Q1FY24.

Net profit is seen increasing merely three percent on year to Rs 442.4 crore in the June quarter.

L&T recently announced its first-ever share buyback. Details of the buyback, along with the special dividend, will be disclosed by the company today, while announcing the results. Market participants are keenly awaiting these details.

Continued boost from sales of the blockbuster drug Revlimid along with launches of a few inhalation drug is expected to fuel a jump in US sales for Dr Reddys.

Most brokerages see Cipla as the frontrunner of growth within the domestic market in Q1 which will help offset the adverse impact of a moderation in US sales.

Brokerages hint at a weak April-June quarter for chemical companies, marred by pricing pressure, weakening demand and eroding margins.

According to a mean consensus of four brokerage firms, the company is expected to report a Revenue of Rs 17,475 crore in Q1FY24. This is supposed to be a 15.2 percent increase YoY from Rs 15,164 crore reported in Q1FY23.

Market participants will monitor sales volume growth and capacity utilisation during January-March quarter

The market will monitor the NTPC management’s commentary on commercial capacity addition and the timeline for the monetisation of stake in the renewable asset subsidiary